Our review differed in emphasis, covering a wider range of therapeutic approaches beyond gene editing, including the latest developments in CFTR modulator therapy, advancements in symptomatic treatments, and improvements in care standards that contribute to the increased life expectancy of CF patients. Here, CFTR is linked to cystic fibrosis.